Kent Lake Capital’s Procept Biorobotics PRCT Stock Holding History

Kent Lake Capital’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15,000	Closed	-$623K	–	47
2022 Q4	$623K	Buy	+15,000	New	+$644K	0.37%	34

Other funds holding PRCT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Kent Lake Capital's PRCT Position: Q1 2023 in Review

Kent Lake Capital sold out of Procept Biorobotics (PRCT) in Q1 2023, closing a stake of 15,000 shares — an estimated $623K sold.

Kent Lake Capital first reported a position in PRCT in Q4 2022 and held it in 1 quarter. The position peaked at $623K in Q4 2022. 116 funds tracked by Wall St. Rank hold PRCT as of Q1 2023.

Kent Lake Capital reported no remaining Procept Biorobotics position as of Q1 2023 after selling out during the quarter.
Kent Lake Capital sold 15,000 Procept Biorobotics shares in Q1 2023, an estimated $623K.
Kent Lake Capital first reported a position in Procept Biorobotics in Q4 2022 and held it in 1 quarter.
Kent Lake Capital's Procept Biorobotics position peaked at $623K in Q4 2022.
116 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2023.

Based on Kent Lake Capital's 13F filing for Q1 2023, filed 15 May 2023.